Alzamend Neuro, Inc.
ALZN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001677077
In the last 90 days, Alzamend Neuro, Inc. insiders filed 1 open-market purchase and 1 sale; 12 institutions reported holding it in 13F filings for Q2 2026, worth $3.26M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $111.0K in total
- 1
- Insider sellsLast 90 days, $3.12K in total
- 1
- 13F holdersQ2 2026, −1 vs. previous quarter
- 12
- 13F valueReported value at the end of Q2 2026
- $3.26M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ALZN, Q2 2026
No superinvestor reported holding ALZN at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Alzamend Neuro, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 31, 2026 (view filing)6:05 AM ET | Aug 26 | 5 daysLate | Ault Milton C IIIDirector | SSale | −2.00K | $1.56 | −$3.12K | −100.0%0 after | |
| Aug 31, 2026 (view filing)6:00 AM ET | Apr 14 | 139 days | Ault Milton C IIIDirector | PPurchase | +108.4K | $1.00 | +$108.9K | +1,312.2%116.6K after | Amended |
| Aug 31, 2026 (view filing)6:00 AM ET | Apr 14 | 139 days | Ault Milton C IIIDirector | PPurchase | +2.00K | $1.03 | +$2.07K | New position2.00K after | Amended |
| Dec 30, 2025 (view filing) | Dec 23 | 7 days | Ault Milton C IIIDirector | SSale | −1.85K | $2.07 | −$3.83K | −100.0%0 after | |
| Dec 23, 2025 (view filing) | Dec 19 | 4 days | Horne William B.Director | SSale | −3.33K | $2.12 | −$7.07K | −100.0%0 after | |
| Oct 24, 2025 (view filing) | Oct 23 | 1 day | McGrath Lynne FaheyDirector | SSale | −30 | $2.29 | −$68.7 | −54.5%25 after | |
| Oct 10, 2025 (view filing) | Oct 8-9 | 2 days | Ault Milton C IIIDirector | SSale | −121.8K | $2.42 | −$294.7K | −93.6%8.26K after | 2 lots |
| Oct 8, 2025 (view filing) | Oct 6-7 | 2 days | Ault Milton C IIIDirector | SSale | −139.4K | $2.47 | −$343.9K | −66.9%68.8K after | 2 lots |
| Oct 3, 2025 (view filing) | Oct 1-3 | 2 days | Ault Milton C IIIDirector | SSale | −123.4K | $2.40 | −$296.7K | −93.7%8.26K after | 3 lots |
| Sep 30, 2025 (view filing) | Sep 26-30 | 4 days | Ault Milton C IIIDirector, 10% Owner | SSale | −79.6K | $2.31 | −$184.0K | −71.6%31.6K after | 3 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Alzamend Neuro, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Kingsbury Capital Investment Advisors LLC | 1,329,100 | $1.59M | 1.35% | +762,367+134.5% | Added |
| KMT Wealth Management, LLC | 1,329,100 | $1.59M | 1.35% | +1,329,100 | New |
| Geode Capital Management, LLC | 26,371 | $31.6K | 0.00% | −19,309−42.3% | Reduced |
| Vanguard Fiduciary Trust Co | 21,020 | $25.2K | 0.00% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 7,556 | $9.07K | 0.00% | +3,156+71.7% | Added |
| Tower Research Capital LLC (TRC) | 3,517 | $4.22K | 0.00% | −2,667−43.1% | Reduced |
| UBS Group AG | 2,352 | $2.82K | 0.00% | −2,152−47.8% | Reduced |
| BlackRock, Inc. | 437 | $524 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 22 | $26 | 0.00% | 00.0% | Unchanged |
| IFG Advisory, LLC | 22 | $26 | 0.00% | +22 | New |